- Design
- randomised, double-blind, placebo-controlled trial over 8 weeks
- Population
- 60 adults aged 40 to 75 with mild to moderate knee osteoarthritis
- Primary outcome
- total WOMAC score, with subscales, visual analogue scale and high-sensitivity C-reactive protein
- Effect
- significant reduction in total WOMAC, pain, stiffness and visual analogue score versus placebo (P<0.05); effect sizes not reported in the abstract
Boswellia serrata is one of the most widely taken things in Indian osteoarthritis practice and one of the least often tested properly, so a randomised double-blind placebo-controlled trial deserves reading rather than dismissing. Sixty people aged 40 to 75 with mild to moderate knee osteoarthritis received either 100 mg once daily of a standardised extract (OLNP-27) or placebo for eight weeks, with WOMAC total and subscale scores and a visual analogue scale measured at days 7, 15, 30 and 60.
The extract reduced total WOMAC score, pain, stiffness and visual analogue score and improved physical function compared with placebo (P<0.05 throughout), and reduced high-sensitivity C-reactive protein. The separation in pain and stiffness was present by day 7, which the authors take as evidence of rapid onset. It was well tolerated.
The design is sound in structure and thin in substance. Sixty participants, eight weeks, and — importantly — the abstract reports significance without effect sizes, so how much WOMAC actually improved cannot be stated. That matters, because WOMAC responds strongly to placebo in osteoarthritis and the question is never whether a difference exists but whether it reaches the minimum clinically important difference. A statistically significant change of three WOMAC points and one of fifteen look identical in an abstract that reports only P values.
The C-reactive protein reduction is the more interesting signal, since it is harder to produce by expectation, though in mild to moderate knee osteoarthritis baseline C-reactive protein is usually near normal and small absolute changes are easy to over-read. The honest position for a clinician asked about it: this is a reasonably designed small trial supporting what patients are already doing, not a reason to recommend it over exercise and weight management, which remain the interventions with the largest effects.
- Do not displace exercise, weight management and analgesia; those remain the evidence base
- If a patient is already taking Boswellia, there is no reason on these data to stop it
- Ask which preparation and what standardisation — extracts differ greatly and this trial tested one specific product
- Treat the absence of reported effect sizes as a reason to withhold judgement on magnitude
- Check for interactions and note it is a supplement, not a regulated medicine, so batch consistency is not guaranteed
The statistics, in plain English
P<0.05 without an effect size is the central limitation here: in knee osteoarthritis the placebo response on WOMAC is large, so statistical significance says a difference exists while leaving open whether it crosses the minimum clinically important difference — usually taken as around 10 points on total WOMAC. Sixty participants over eight weeks also cannot address durability or rarer harms. Separation by day 7 is striking but plausible for an anti-inflammatory mechanism, and equally plausible as early placebo divergence in a symptom measured by questionnaire.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for rheumatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free